🚀 VC round data is live in beta, check it out!
Elicio Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Elicio Therapeutics and similar public comparables like Caribou Biosciences, Tonix Pharmaceuticals, Karyopharm Therapeutics, Sagimet Biosciences and more.
Elicio Therapeutics Overview
About Elicio Therapeutics
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
Founded
2011
HQ
Employees
32
Website
Sectors
Financials (LTM)
EV
$185M
Elicio Therapeutics Financials
Elicio Therapeutics reported last 12-month revenue of —.
In the same LTM period, Elicio Therapeutics generated had net loss of ($38M).
Revenue (LTM)
Elicio Therapeutics P&L
In the most recent fiscal year, Elicio Therapeutics reported revenue of — and EBITDA of ($37M).
Elicio Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($37M) | XXX | XXX | XXX |
| Net Profit | ($38M) | XXX | ($40M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Elicio Therapeutics Stock Performance
Elicio Therapeutics has current market cap of $189M, and enterprise value of $185M.
Market Cap Evolution
Elicio Therapeutics' stock price is $10.29.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $185M | $189M | 1.7% | XXX | XXX | XXX | $-2.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialElicio Therapeutics Valuation Multiples
Elicio Therapeutics trades at (5.0x) EV/EBITDA.
Elicio Therapeutics Financial Valuation Multiples
As of April 11, 2026, Elicio Therapeutics has market cap of $189M and EV of $185M.
Equity research analysts estimate Elicio Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Elicio Therapeutics has a P/E ratio of (5.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $189M | XXX | $189M | XXX | XXX | XXX |
| EV (current) | $185M | XXX | $185M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.0x) | XXX | XXX | XXX |
| EV/EBIT | (5.0x) | XXX | (5.0x) | XXX | XXX | XXX |
| P/E | (5.0x) | XXX | (4.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Elicio Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Elicio Therapeutics Margins & Growth Rates
Elicio Therapeutics' revenue in the last fiscal year grew by —.
Elicio Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.2M for the same period.
Elicio Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (26%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Elicio Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Caribou Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Tonix Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Karyopharm Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sagimet Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Protalix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Elicio Therapeutics M&A Activity
Elicio Therapeutics acquired XXX companies to date.
Last acquisition by Elicio Therapeutics was on XXXXXXXX, XXXXX. Elicio Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Elicio Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialElicio Therapeutics Investment Activity
Elicio Therapeutics invested in XXX companies to date.
Elicio Therapeutics made its latest investment on XXXXXXXX, XXXXX. Elicio Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Elicio Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Elicio Therapeutics
| When was Elicio Therapeutics founded? | Elicio Therapeutics was founded in 2011. |
| Where is Elicio Therapeutics headquartered? | Elicio Therapeutics is headquartered in United States. |
| How many employees does Elicio Therapeutics have? | As of today, Elicio Therapeutics has over 32 employees. |
| Who is the CEO of Elicio Therapeutics? | Elicio Therapeutics' CEO is Robert Connelly. |
| Is Elicio Therapeutics publicly listed? | Yes, Elicio Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Elicio Therapeutics? | Elicio Therapeutics trades under ELTX ticker. |
| When did Elicio Therapeutics go public? | Elicio Therapeutics went public in 2023. |
| Who are competitors of Elicio Therapeutics? | Elicio Therapeutics main competitors are Caribou Biosciences, Tonix Pharmaceuticals, Karyopharm Therapeutics, Sagimet Biosciences. |
| What is the current market cap of Elicio Therapeutics? | Elicio Therapeutics' current market cap is $189M. |
| Is Elicio Therapeutics profitable? | No, Elicio Therapeutics is not profitable. |
| What is the current net income of Elicio Therapeutics? | Elicio Therapeutics' last 12 months net income is ($38M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.